Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271

(2017) A Natoni et al.   LEUKEMIA

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma

(2016) Barbara Muz et al.   BRITISH JOURNAL OF HAEMATOLOGY

3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma

(2015) Pilar de la Puente et al.   BIOMATERIALS

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib

(2015) Barbara Muz et al.   Biomed Research International

The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma

(2014) S. V. Glavey et al.   BLOOD

Hypoxia promotes stem cell-like phenotype in multiple myeloma cells

(2014) B Muz et al.   Blood Cancer Journal

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features

(2012) A. K. Azab et al.   BLOOD

P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment

(2011) A. K. Azab et al.   BLOOD

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

(2009) A. K. Azab et al.   BLOOD